Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.
The Ewha Medical Journal
Ewha Womans University School of Medicine

Ewha Med J 2003; 26(1):33-37

pISSN: 1598-7450

DOI: https://doi.org/10.12771/emj.2003.26.1.33

Original Article

The Clinical Efficacy and Safety of TAGOCIN® inj

Mina Yu, Sun Hee Maeng, Young Joo Cho

Copyright ⓒ 2003. Ewha Womans University School of Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published Online: Mar 31, 2003

Abstract

Objectives

We studied the open clinical trial to evaluate the efficacy and safety of TAGOCIN®, teicoplanin, glycopeptide anti microbial agent, which was manufactured in one Korean pharmacy.

Methods

We selected 15 patients hospitalized with presumed or proven infection due to gram positive organism, judged to require glycopeptiede and administered by intravenous bolus injection at a dose of 200mg TAGOCIN® per day. The efficacy was assessed by bacteriological result, clinical symptom and radiological change.

Results

Mean age of 15 patients treated is 66. 13 cases were lower respiratory tract infection, I case was urinary tract infection and I case was soft tissue infection. Gram positive organism was isolated in Seven samples of five patients, and at four patients of them, gram positive organism were eliminated. During treatment, one patients liver enzyme elevated mildly.

Conclusion

TAGOCIN® is an effective and tolerated antibiotics against gram positive organism in severe infected patients.

Keywords: Teicoplanin; TAGOCID®; Methicillin resistant staphlococcus aureus(MRSA)